Tremendous upside with its MANF technology to treat Parkinson's disease.
300-500% upside by 12/31/2012.
Buy a few shares today under five cents.
"Big pharma" development partnership takes it to $1.00 in 2013.
The market is just finding out about the company's potential.
Read the recent Yahoo news.
Co-founder of Amgen recently joined the company's board of directors.
Substantially undervalued here.